Latin America Insulin Market Size & Outlook, 2024-2030

The insulin market in Latin America is expected to reach a projected revenue of US$ 1,039.7 million by 2030. A compound annual growth rate of 5.3% is expected of Latin America insulin market from 2025 to 2030.
Revenue, 2024 (US$M)
$793.5
Forecast, 2030 (US$M)
$1,039.7
CAGR, 2025 - 2030
5.3%
Report Coverage
Latin America

Latin America insulin market highlights

  • The Latin America insulin market generated a revenue of USD 793.5 million in 2024.
  • The market is expected to grow at a CAGR of 5.3% from 2025 to 2030.
  • In terms of segment, insulin analog was the largest revenue generating type in 2024.
  • Insulin Analog is the most lucrative type segment registering the fastest growth during the forecast period.
  • Country-wise, Argentina is expected to register the highest CAGR from 2025 to 2030.

Latin America data book summary

Market revenue in 2024USD 793.5 million
Market revenue in 2030USD 1,039.7 million
Growth rate5.3% (CAGR from 2025 to 2030)
Largest segmentInsulin analog
Fastest growing segmentInsulin Analog
Historical data covered2018 - 2023
Base year for estimation2024
Forecast period covered2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationInsulin Analog, Human Insulin
Key market players worldwideNovo Nordisk A/S ADR, Eli Lilly and Co, Sanofi SA, United Laboratories International Holdings Ltd, Biocon, Wockhardt, Boehringer Ingelheim Pharma, Tonghua Dongbao Pharmaceutical, Julphar

Other key industry trends

  • In terms of revenue, Latin America region accounted for 4.1% of the global insulin market in 2024.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 7,094.5 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Insulin Market Companies

Name Profile # Employees HQ Website

Latin America insulin market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to insulin market will help companies and investors design strategic landscapes.


Insulin analog was the largest segment with a revenue share of 88.41% in 2024. Horizon Databook has segmented the Latin America insulin market based on insulin analog, human insulin covering the revenue growth of each sub-segment from 2018 to 2030.


A large section of the society in South America is aging rapidly, which has led to an increase in healthcare expenditure and is driving market growth in the region. The increasing focus of multinational pharmaceutical companies on this region is expected to drive market growth over the forecast period.

For instance, in June 2019, Geropharm and Espromed Bio signed an agreement to localize their production & supply of insulin in Venezuela. Under this agreement, Russian company Geropharm established production of insulin from active ingredients supplied from Russia. The volume of production was nearly 8 million bottles per year.

Brazil is expected to witness significant growth due to an increase in prevalence of diabetes. As per the IDF Diabetes Atlas, around 15.7 million people were living with diabetes in Brazil in 2021. This number is expected to reach around 19.2 million by 2030.

Reasons to subscribe to Latin America insulin market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Latin America insulin market databook

  • Our clientele includes a mix of insulin market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America insulin market , including forecasts for subscribers. This continent databook contains high-level insights into Latin America insulin market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Latin America insulin market size, by country, 2018-2030 (US$M)

Latin America Insulin Market Outlook Share, 2024 & 2030 (US$M)

Latin America insulin market size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more